Lectenz Bio receives NIH SBIR Phase II

Lectenz Bio receives NIH SBIR Phase II

The National Institute of General Medical Sciences (NIGMS) awards Lectenz Bio an SBIR Phase II to further develop sialic acid Lectenz®.